medigraphic.com
Revista Médica Sinergia

2020, Number 04

<< Back

Revista Médica Sinergia 2020; 5 (04)

Diabetic peripheral neuropathy in the urban type II ambulatory Dr. Gualdrón of Barquisimeto, Venezuela

Agobian G, Traviezo VLE

Language: Spanish
References: 25
Page: 1-9
PDF size: 149.96 Kb.


ABSTRACT

Introduction: Diabetic peripheral neuropathy was characterized in patients with Diabetes Mellitus Type 2, in the urban type II ambulatory Dr. Gualdrón of Barquisimeto, Venezuela. Methods: An observational descriptive study, the sample was non-probabilistic, accidental, consisting of the first 60 patients who gave their informed consent; The Michigan Neuropathy Screening Instrument was applied. Results: Diabetic peripheral neuropathy was detected in 60% of the patients, of these 33.3% showed symptoms, 83.3% presented alterations in the appearance of the feet, 11.1% ulceration in the feet, 55.6% reflexes reinforced Aquilians and 19.4% absence thereof. The vibrational perception of Hallux 13.9% was reduced and 47.2% absent. The sensitivity to monofilament in 38.9% was reduced and in 19.4% absent. Likewise, 78.3% corresponded to the male sex and 48.6% to the female sex, 88.9% to the group ≥ 70 years, 63.6% indicated 10 or more years as diabetic and 63% did not had adherence to drug treatment. Conclusions: It is evident that the frequency of Diabetic peripheral neuropathy is high, it was higher in men and in the group ≥ 70 years old, the main lesions identified were abnormality in the appearance of the feet and sensitivity alterations. Faced with such a health problem, it is necessary to establish preventive actions aimed at preventing deterioration in the patient's quality of life. Therefore, this type of assessment is important to avoid complications.


REFERENCES

  1. Selvarajah D, Kar D, Khunti K, Davies M, Scott A, Walker J, et al. Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. The Lancet Diabetes & Endocrinology. 2019; 7(12):938-948. https://doi.org/10.1016/S2213-8587(19)30081-6

  2. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2017;40:S11- S24.2. https://doi.org/10.2337/dc17-S005

  3. Diagnóstico y tratamiento de la neuropatía diabética en adultos. Guía de Práctica Clínica: Guía de Evidencias y Recomendaciones CENETEC 2017. URL:http://www.cenetec.salud.gob.mx/contenidos/gpc/catalogoMaestro-GPC.html

  4. Tanenberg R. Diabetic Peripheral Neuropathy: Painful or Painless. Hospital Physician.2009;45(7):1- 8.URL: https://www.researchgate.net/publication/233763397_Diabetic_Neuropathy_Painful_or_Painless

  5. Tesfaye S, Selvarajah D. Diabetes Metabolism Research and Reviews 2012;28(S1):8- 14. https://doi.org/10.1002/dmrr.2239

  6. Botas M, Cervell D, Montalbán AR, Jiménez SV, Valderrama R. Actualización en el diagnóstico, tratamiento y prevención de la neuropatía diabética periférica. Angiología. 2017;69(3):174- 81. https://doi.org/10.1016/j.angio.2016.06.005

  7. Márquez SA, Zonana A, Anzaldo MC, Muñoz JA. Riesgo de pie diabético en pacientes con diabetes mellitus tipo 2 en una unidad de medicina de familia. SEMERGEN-Medicina de familia. 2014;40(4):183-

  8. https://doi.org/10.1016/j.semerg.2013.10.004 8. Won JC, Park TS. Recent Advances in Diagnostic Strategies for Diabetic Peripheral Neuropathy Endocrinol Metab. 2016;31(2):230-238. https://doi.org/10.3803/EnM.2016.31.2.230

  9. Pop-Busui R, Boulton A, Feldman E, Bril V, Freeman R, Malik R, Sosenko J, Ziegler D. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(1):136- 154. https://doi.org/10.2337/dc16-2042

  10. Vera B, Perkins B, Toth C. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: pharmacologic management of type 2 diabetes. Can J Diabetes 2013; 37 (suppl1): S142-S144. https://doi.org/10.1016/j.jcjd.2013.01.039

  11. Aliss S, Cervantes R, Ibarra O, González B. Prevalencia de Neuropatía Periférica en Diabetes Mellitus. Acta Médica Grupo Ángeles 2006; 4(1):12-17. URL: https://www.medigraphic.com/cgibin/ new/resumen.cgi?IDARTICULO=5356

  12. Ticse R, Pimentel R, Mazzeti P, Villena J. Elevada frecuencia de neuropatía periférica en pacientes con Diabetes mellitus tipo 2 de un Hospital General de Lima-Perú. Rev Med Hered. 2013; 24:114- 121. https://doi.org/10.20453/rmh.v24i2.593

  13. Secretaría de Salud de Honduras. Guía de práctica clínica para el manejo ambulatorio (promoción, prevención, diagnóstico y tratamiento) del adulto con Diabetes Mellitus tipo 2. 2015. 292p. URL: http://www.bvs.hn/Honduras/pdf/GPC.DMT2.pdf

  14. Deli G, Bosnyak E, Pusch G Komoly S, Feher G. Diabetic Neuropathies: Diagnosis and Management. Neuroendrocrinology. 2013;98(4):267-80.https://doi.org/10.1159/000358728

  15. Millan R, Clemente C, Isaís S, Trujillo B, Caballero R. Asociación entre la presencia de enfermedad vascular periférica y neuropatía en pacientes con diabetes mellitus tipo 2. Rev Invest Clin. 2011;63(6):621-9.

  16. Moghtaderi A, Backhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg 2006; 108 (5):477- 81. https://doi.org/10.1016/j.clineuro.2005.08.003

  17. Mayfield J, Sugarman J. The use of the Semmes-Weinstein monofilament and other threshold tests for preventing foot ulceration and amputation in persons with diabetes. J Fam Pract. 2000; 49: S17-S29. URL: https://go.gale.com/ps/anonymous?id=GALE%7CA68145604&sid=googleScholar&v=2.1&it=r&linkac cess=abs&issn=00943509&p=AONE&sw=w

  18. Ibarra C, Rocha J, Hernández R, Nieves R, Leyva R. Prevalencia de neuropatía periférica en diabéticos tipo 2 en el primer nivel de atención. Rev. Méd. Chile. 2012; 140 (9): 1126- 1131. https://doi.org/10.4067/S0034-98872012000900004

  19. Michigan Neuropathy Screening Instrument. How to Use the Michigan Neuropathy Screening Instrument. 2000. URL: https://www.med.umich.edu/mdrtc/profs/documents/svi/MNSI_howto.pdf

  20. Oliveros L, Ávila P, Ulloa V, Bernabe A. Calidad de vida en pacientes con neuropatía diabética periférica: estudio transversal en Lima, Perú. Acta Médica Peruana. 2018;35(3):160-7 URL: http://www.scielo.org.pe/pdf/amp/v35n3/a04v35n3.pdf.

  21. Flores I, Cuevas Z, López R, Vásquez C. Detección de Neuropatía Diabética Periférica en Adultos Mayores de 60 Años en el Centro de Salud "México BID" de Colima, México. Archivos de Medicina. 2018;14,4:1 URL: http://www.archivosdemedicina.com/medicina-de-familia/deteccioacuten-deneuropatiacutea- diabeacutetica-perifeacuterica-en-adultos-mayores-de-60-antildeos-en-el-centro-desalud- meacutex.pdf

  22. Lerman GI. La atención del paciente más allá del primer nivel de atención. salud pública de México 2007; 49 (número especial): 99-103. URL: https://www.researchgate.net/publication/237022665_La_atencion_del_paciente_mas_alla_del_prim er_nivel_de_atencion

  23. Jiménez V. Incidencia de neuropatía diabética con el Test de Michigan en la UMF 61. 2015. Tesis especialidad en Medicina Familiar. Universidad Veracruzana, México.

  24. Rivas V, Yadira Y, García H, Martínez A, Magaña M, Carrillo R. Evaluación integral de la sensibilidad en los pies de las personas con Diabetes Mellitus tipo 2. Rev Cuid. 2017; 8(1): 1423- 1432. https://doi.org/10.15649/cuidarte.v8i1.348

  25. Godoy E. Factores asociados a neuropatía periférica en diabéticos de 40 a 79 años desde una perspectiva familiar en Loja Ecuador. 2017 URL: http://dspace.unl.edu.ec:9001/jspui/bitstream/123456789/18375/1/ELISA%20GODOY%20BIBLIOTE CA.pdf




2020     |     www.medigraphic.com